section name header

Information

Editors

TomPettersson

Systemic Sclerosis

Essentials

  • Systemic sclerosis is characterized by small vessel injuries, immunological abnormalities, and induration and shrinking of connective tissue.
  • Scleroderma refers to the skin manifestations of systemic sclerosis. Systemic sclerosis and scleroderma are often used as synonyms.
  • Systemic sclerosis is classified into a diffuse and a limited form.

Epidemiology

  • The prevalence of systemic sclerosis is 100-200 cases per one million people.
  • The incidence is highest in women aged 30-50 years.

Symptoms

  • Raynaud's phenomenon (see Raynaud's Phenomenon (RP) or White Finger Disease) can be observed in almost every patient, and it often precedes other symptoms of the disease. The condition may lead to ulcerations and scars on the fingertips and toes.
  • Skin changes occur, especially in the face, hands and feet. First there is swelling of the skin, then thickening and finally atrophy (picture 1). In the limited form of the disease the skin lesions occur in the face and in the extremities distal to the knees and elbows, whereas in diffuse systemic sclerosis the skin symptoms are more widespread.
  • Telangiectasies may be seen.
  • 20-30% of all patients have arthralgia and myalgia.
  • There may be symptoms from the gastrointestinal tract, particularly dysphagia, reflux oesophagitis and oesophageal strictures. Malabsorption, obstipation and faecal incontinence may be present.
  • Lung fibrosis, pulmonary hypertension
  • Heart failure, arrhythmias
  • Proteinuria, impaired renal function and elevated blood pressure are not rare. The most severe renal complication is the scleroderma renal crisis characterized by highly elevated blood pressure, rapidly progressing renal failure and microangiopathic haemolytic anaemia.

Investigations and diagnosis

  • When suspecting systemic sclerosis, the following investigations are recommended to be take within primary health care: ESR, CRP, basic blood count with platelet count, antinuclear antibodies, creatinine, chemical urinalysis.
  • The combination of Raynaud's phenomenon, swollen fingers and a positive result in antinuclear antibody test is regarded as a "red flag", which should lead to suspecting early systemic sclerosis and a consultation within specialized health care.
  • The diagnosis of systemic sclerosis is confirmed within specialized care. The most important further investigations include determination of specific autoantibodies (anticentromere antibodies and type I topoisomerase, i.e. Scl-70 antibodies), videocapillaroscopy and, if needed, skin biopsy.
  • ESR is often moderately increased in systemic sclerosis, but CRP is normal or slightly elevated. Basic blood count is usually normal; leucopenia and thrombocytopenia occur clearly less frequently than in SLE. Antinuclear antibodies are found in about 90%. Nucleolar staining pattern is typically either speckled or nucleolar.
  • Centromere antibodies are found in those with the limited disease form (previously the CREST syndrome , i.e. calcinosis, Raynaud's phenomenon, oesophageal hypomotility, sclerodactyly, teleangiectasies). This disease form is associated with the risk of elevated pulmonary artery pressure.
  • Type I topoisomerase antibodies are usually associated with the diffuse disease and an increased risk of pulmonary fibrosis.
  • Videocapillaroscopy is an important method in distinguishing between primary and secondary Raynaud's phenomenon. Changes in the nailfold capillaries are found in over 80% of patients with systemic sclerosis, and the abnormalities correlate with the severity of the disease.
  • A chest radiography helps to assess the pulmonary status. High-resolution computed tomography and pulmonary function tests are often necessary further investigations.
  • Subcutaneous calcifications and acrolysis in the fingers, both typical for the disease, may be found in radiographs of the hands and feet.
  • With respect to the gastrointestinal system, the most important investigation is oesophagogastroduodenoscopy.

Treatment Calcium-Channel Blockers for Raynaud's Phenomenon in Systemic Sclerosis, Iloprost and Cisaprost for Raynaud's Phenomenon in Progressive Systemic Sclerosis, Methotrexate in the Treatment of Systemic Sclerosis, Proton Pump Inhibitors, H2-Receptor Antagonists and Prokinetics for Gastro-Oesophageal Reflux, Cyclophosphamide for Connective Tissue Disease-Associated Interstitial Lung Disease, Angiotensin Converting Enzyme Inhibitors in Treatment of Scleroderma Renal Crisis, Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension, Phosphodiesterase 5 Inhibitors for Pulmonary Hypertension, Inhaled Iloprost for Pulmonary Hypertension, Interventions for Morphea, Phosphodiesterase 5 Inhibitors for Raynaud's Phenomenon

Prognosis

  • Favourable when the disease is confined to the skin
  • Pulmonary hypertension and respiratory or renal failure are factors that compromise the prognosis.

Related Keywords

ATC Code:

L01AA01

C02KX01

A02BC01

A02BC02

A02BC03

A02BC04

A02BC05

C09CA01

C09CA02

C09CA03

C09CA04

C09CA06

C09CA07

C09CA08

H02AB01

H02AB02

H02AB04

H02AB06

H02AB07

H02AB08

H02AB09

H02AB13

H02BX01

M01AB01

M01AB02

M01AB05

M01AB08

M01AB15

M01AB51

M01AB55

M01AC01

M01AC02

M01AC06

M01AE01

M01AE02

M01AE03

M01AE11

M01AE17

M01AE51

M01AE52

M01AG01

M01AG02

M01AX01

M01AX17

N02AJ08

N02BA01

N02BA51

N02BA57

L04AX03

C09AA01

C09AA02

C09AA03

C09AA04

C09AA05

C09AA06

C09AA15

N06AB03

N06AB04

N06AB05

N06AB06

N06AB08

N06AB10

L04AX01

L01XC02

Primary/Secondary Keywords